Written Answers — Department of Health and Social Care: Novel Foods (21 Jun 2022) Maggie Throup: The Food Standards Agency (FSA) regularly meets with its counterpart food safety regulators and discusses novel foods and
Written Answers — Department of Health and Social Care: Novel Foods (21 Jun 2022) Maggie Throup: The Foods Standards Agency (FSA) has committed to review the novel foods regulations.
Written Answers — Department of Health and Social Care: Hepatitis (21 Jun 2022) Maggie Throup: The Community Pharmacy Hepatitis C Antibody Testing Service ensures that people who inject drugs who are not currently acc
Written Answers — Department of Health and Social Care: Hepatitis (21 Jun 2022) Maggie Throup: The UK Health Security Agency (UKHSA) publishes an annual report which summarises the prevalence of hepatitis C infection
Written Answers — Department of Health and Social Care: Monkeypox: Disease Control (21 Jun 2022) Maggie Throup: The UK Health Security Agency (UKHSA) is working with system partners to understand the transmission of monkeypox and whic
Written Answers — Department of Health and Social Care: Life Expectancy (20 Jun 2022) Maggie Throup: We will set out a strategy to address the causes of health inequalities in the health disparities white paper, which we ex
Written Answers — Department of Health and Social Care: Gambling: Rehabilitation (20 Jun 2022) Maggie Throup: The Department has responsibility for the treatment of gambling-related harms in England.
Written Answers — Department of Health and Social Care: Evusheld (20 Jun 2022) Maggie Throup: The Department is currently conducting its assessment of Evusheld, which includes advice from clinicians in line with avai
Written Answers — Department of Health and Social Care: Food: Advertising (20 Jun 2022) Maggie Throup: We have announced a delay to the implementation of the volume price promotions restrictions and the introduction of furthe
Written Answers — Department of Health and Social Care: Coronavirus: Vaccination (20 Jun 2022) Maggie Throup: The Medicines and Healthcare products Regulatory Agency (MHRA) has monitored emerging information concerning Guillain-Barr